Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.34
CBST's Cash to Debt is ranked higher than
51% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. CBST: 0.34 )
CBST' s 10-Year Cash to Debt Range
Min: 0.19   Max: 35.27
Current: 0.34

0.19
35.27
Equity to Asset 0.46
CBST's Equity to Asset is ranked higher than
59% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CBST: 0.46 )
CBST' s 10-Year Equity to Asset Range
Min: -0.48   Max: 0.95
Current: 0.46

-0.48
0.95
Interest Coverage 7.19
CBST's Interest Coverage is ranked higher than
51% of the 408 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CBST: 7.19 )
CBST' s 10-Year Interest Coverage Range
Min: 0.31   Max: 7.41
Current: 7.19

0.31
7.41
F-Score: 3
Z-Score: 2.15
M-Score: -2.16
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 25.60
CBST's Operating margin (%) is ranked higher than
94% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. CBST: 25.60 )
CBST' s 10-Year Operating margin (%) Range
Min: -2763   Max: 29.79
Current: 25.6

-2763
29.79
Net-margin (%) 16.63
CBST's Net-margin (%) is ranked higher than
91% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. CBST: 16.63 )
CBST' s 10-Year Net-margin (%) Range
Min: -3094.81   Max: 29.49
Current: 16.63

-3094.81
29.49
ROE (%) 15.55
CBST's ROE (%) is ranked higher than
93% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -20.84 vs. CBST: 15.55 )
CBST' s 10-Year ROE (%) Range
Min: -367.03   Max: 48.78
Current: 15.55

-367.03
48.78
ROA (%) 7.97
CBST's ROA (%) is ranked higher than
92% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. CBST: 7.97 )
CBST' s 10-Year ROA (%) Range
Min: -56.63   Max: 18.56
Current: 7.97

-56.63
18.56
ROC (Joel Greenblatt) (%) 142.44
CBST's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -247.50 vs. CBST: 142.44 )
CBST' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -538.43   Max: 230
Current: 142.44

-538.43
230
Revenue Growth (%) 11.40
CBST's Revenue Growth (%) is ranked higher than
85% of the 624 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. CBST: 11.40 )
CBST' s 10-Year Revenue Growth (%) Range
Min: -41.3   Max: 209.9
Current: 11.4

-41.3
209.9
EBITDA Growth (%) 13.20
CBST's EBITDA Growth (%) is ranked higher than
89% of the 598 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. CBST: 13.20 )
CBST' s 10-Year EBITDA Growth (%) Range
Min: -46.9   Max: 93.6
Current: 13.2

-46.9
93.6
EPS Growth (%) 17.70
CBST's EPS Growth (%) is ranked higher than
91% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. CBST: 17.70 )
CBST' s 10-Year EPS Growth (%) Range
Min: -86   Max: 37.9
Current: 17.7

-86
37.9
» CBST's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

CBST Guru Trades in Q3 2013

Andreas Halvorsen 594,704 sh (New)
John Burbank 202,451 sh (New)
Pioneer Investments 686,436 sh (+357.01%)
Chuck Royce 425,800 sh (+29.74%)
RS Investment Management 622,011 sh (+25.03%)
Vanguard Health Care Fund 1,323,142 sh (unchged)
Murray Stahl 24,000 sh (unchged)
Stanley Druckenmiller 413,000 sh (unchged)
Joel Greenblatt 25,996 sh (unchged)
Michael Price Sold Out
George Soros 150,000 sh (-14.29%)
Jim Simons 324,620 sh (-29.77%)
Steven Cohen 60,503 sh (-33%)
» More
Q4 2013

CBST Guru Trades in Q4 2013

Paul Tudor Jones 3,348 sh (New)
Andreas Halvorsen 741,700 sh (+24.72%)
Vanguard Health Care Fund 1,323,142 sh (unchged)
Stanley Druckenmiller 413,000 sh (unchged)
Murray Stahl 24,000 sh (unchged)
John Burbank Sold Out
Joel Greenblatt Sold Out
George Soros 144,500 sh (-3.67%)
RS Investment Management 536,011 sh (-13.83%)
Pioneer Investments 515,939 sh (-24.84%)
Chuck Royce 307,800 sh (-27.71%)
Steven Cohen 30,257 sh (-49.99%)
Jim Simons 125,920 sh (-61.21%)
» More
Q1 2014

CBST Guru Trades in Q1 2014

Lee Ainslie 1,739,818 sh (New)
Jim Simons 189,091 sh (+50.17%)
Murray Stahl 24,000 sh (unchged)
Vanguard Health Care Fund 1,323,142 sh (unchged)
Stanley Druckenmiller Sold Out
Andreas Halvorsen Sold Out
Paul Tudor Jones Sold Out
RS Investment Management 504,845 sh (-5.81%)
Chuck Royce 219,900 sh (-28.56%)
Pioneer Investments 368,542 sh (-28.57%)
George Soros 50,000 sh (-65.4%)
Steven Cohen 3,082 sh (-89.81%)
» More
Q2 2014

CBST Guru Trades in Q2 2014

Ken Fisher 36,450 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with CBST

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Lee Ainslie 2014-03-31 New Buy1.8%$67.2 - $81.23 $ 61.4-18%1739818
George Soros 2014-03-31 Reduce -65.4%0.06%$67.2 - $81.23 $ 61.4-18%50000
John Burbank 2013-12-31 Sold Out 0.42%$61.59 - $70.76 $ 61.4-5%0
Joel Greenblatt 2013-12-31 Sold Out 0.05%$61.59 - $70.76 $ 61.4-5%0
Michael Price 2013-09-30 Sold Out 1.2%$51.58 - $66.54 $ 61.41%0
John Burbank 2013-09-30 New Buy0.42%$51.58 - $66.54 $ 61.41%202451
George Soros 2013-06-30 New Buy0.09%$44.66 - $56.11 $ 61.425%175000
John Hussman 2013-03-31 Sold Out 0.75%$40.78 - $48.06 $ 61.439%0
Joel Greenblatt 2013-03-31 Reduce -72.24%0.18%$40.78 - $48.06 $ 61.439%28134
Joel Greenblatt 2012-12-31 New Buy0.25%$39.17 - $48.63 $ 61.443%101334
Joel Greenblatt 2012-09-30 Sold Out 0.12%$37.91 - $49.83 $ 61.440%0
Joel Greenblatt 2012-06-30 Add 49.02%0.04%$38.38 - $44.07 $ 61.450%41492
John Hussman 2012-03-31 Add 47.16%0.18%$38.77 - $44.72 $ 61.459%674000
Joel Greenblatt 2012-03-31 Reduce -55.29%0.17%$38.77 - $44.72 $ 61.459%27844
George Soros 2012-03-31 Sold Out 0.09%$38.77 - $44.72 $ 61.459%0
Joel Greenblatt 2011-12-31 Reduce -53.85%0.42%$34.05 - $40.38 $ 61.464%62273
John Hussman 2011-12-31 Add 798.04%0.26%$34.05 - $40.38 $ 61.464%458000
George Soros 2011-12-31 Reduce -50%0.03%$34.05 - $40.38 $ 61.464%50000
Michael Price 2011-09-30 Add 73.57%0.49%$29.59 - $36.93 $ 61.480%182500
Joel Greenblatt 2011-09-30 Reduce -37.67%0.41%$29.59 - $36.93 $ 61.480%134927
Vanguard Health Care Fund 2011-09-30 Add 49.25%0.08%$29.59 - $36.93 $ 61.480%1323142
John Hussman 2011-09-30 New Buy0.03%$29.59 - $36.93 $ 61.480%51000
George Soros 2011-09-30 Reduce -26.2%0.02%$29.59 - $36.93 $ 61.480%100000
Joel Greenblatt 2011-06-30 Add 110.97%0.57%$25.14 - $38.53 $ 61.479%216472
Michael Price 2011-06-30 New Buy0.55%$25.14 - $38.53 $ 61.479%105145
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.20
CBST's P/B is ranked higher than
82% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 5.80 vs. CBST: 3.20 )
CBST' s 10-Year P/B Range
Min: 1.85   Max: 81.28
Current: 3.2

1.85
81.28
P/S 4.12
CBST's P/S is ranked higher than
87% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 18.96 vs. CBST: 4.12 )
CBST' s 10-Year P/S Range
Min: 1.98   Max: 150
Current: 4.12

1.98
150
EV-to-EBIT 127.68
CBST's EV-to-EBIT is ranked higher than
85% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBST: 127.68 )
CBST' s 10-Year EV-to-EBIT Range
Min: 4.3   Max: 265.1
Current: 127.68

4.3
265.1
Shiller P/E 49.10
CBST's Shiller P/E is ranked higher than
94% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBST: 49.10 )
CBST' s 10-Year Shiller P/E Range
Min: 22.92   Max: 100.19
Current: 49.1

22.92
100.19
Current Ratio 3.04
CBST's Current Ratio is ranked higher than
68% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. CBST: 3.04 )
CBST' s 10-Year Current Ratio Range
Min: 0.9   Max: 14.48
Current: 3.04

0.9
14.48
Quick Ratio 2.84
CBST's Quick Ratio is ranked higher than
69% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. CBST: 2.84 )
CBST' s 10-Year Quick Ratio Range
Min: 0.81   Max: 14.48
Current: 2.84

0.81
14.48

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 12.80
CBST's Price/Tangible Book is ranked higher than
65% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 8.86 vs. CBST: 12.80 )
CBST' s 10-Year Price/Tangible Book Range
Min: 1.17   Max: 443.2
Current: 12.8

1.17
443.2
Price/DCF (Projected) 2.00
CBST's Price/DCF (Projected) is ranked higher than
96% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBST: 2.00 )
CBST' s 10-Year Price/DCF (Projected) Range
Min: 0.72   Max: 6.09
Current: 2

0.72
6.09
Price/Median PS Value 1.00
CBST's Price/Median PS Value is ranked higher than
84% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. CBST: 1.00 )
CBST' s 10-Year Price/Median PS Value Range
Min: 0.53   Max: 49.32
Current: 1

0.53
49.32
Earnings Yield (Greenblatt) 0.80
CBST's Earnings Yield (Greenblatt) is ranked lower than
58% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 4.70 vs. CBST: 0.80 )
CBST' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.4   Max: 23.3
Current: 0.8

0.4
23.3
Forward Rate of Return (Yacktman) -7.60
CBST's Forward Rate of Return (Yacktman) is ranked higher than
76% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -10.93 vs. CBST: -7.60 )
CBST' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -13.1   Max: 102.6
Current: -7.6

-13.1
102.6

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:CU6.Germany
Cubist Pharmaceuticals, Inc. was incorporated as a Delaware corporation in 1992. It went public in 1996. The Company is engaged in the research, development & commercialization of novel therapies to treat unmet medical needs in acute care environment. It provides CUBICIN, a once-daily, bactericidal, intravenous antibiotic with activity against methicillin-resistant Staphylococcus aureus; and ENTEREG, an oral peripherally-acting mu opioid receptor antagonist to accelerate upper and lower gastrointestinal recovery. The company also co-promotes DIFICID for the treatment of clostridium difficile-associated diarrhea. In addition, its development products include Ceftolozane/tazobactam that is in Phase III clinical trials to treat complicated urinary tract infections and complicated intra-abdominal infections. Further, the company is developing ceftolozane/tazobactam for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Additionally, it develops Surotomycin, an oral lipopeptide, which is in Phase III clinical trials to treat CDAD; Bevenopran, an oral, peripherally-acting mu opioid receptor antagonist for the treatment of opioid-induced constipation in patients with chronic non-cancer pain; and CB-625 that is in Phase I clinical studies to treat acute pain and various inflammatory conditions. In addition, its pre-clinical programs include therapies to treat various bacterial infections and agents to treat acute pain.
» More Articles for CBST

Headlines

Articles On GuruFocus.com
Forest Laboratories Is an Option for Wealthy Investors Who Could Afford to Pay a High Premium Apr 23 2014 
Michael Price’s Top Sells – 11 Gurus Exit SFD Nov 19 2013 
Magic Formula Formulator Joel Greenblatt’s Top 5 New Stock Picks Feb 14 2013 
5 Healthcare Stocks to Consider in 2012 Mar 21 2012 
Cubist Pharmaceutical - Acutely Aware May 09 2010 
Cubist Pharmaceutical - Acutely Aware May 09 2010 
Cubist Pharmaceuticals Inc. Reports Operating Results (10-Q) Apr 29 2010 
Weekly CEO Sells Highlight: Saba Software Inc, Cubist Pharmaceuticals Inc, Polo Ralph Lauren Corp, P Apr 25 2010 
Cubist Pharmaceuticals Inc. (CBST) President and CEO Michael W Bonney sells 184,548 Shares Apr 23 2010 
Cubist Pharmaceuticals: A Drug Stock With Potential For Solid Gain Feb 15 2010 


More From Other Websites
Cubist to Present at August Investor Conference Jul 28 2014
Cubist to Present at August Investor Conference Jul 28 2014
Cubist Misses Q2 Earnings Estimates on Weak Cubicin Sales Jul 23 2014
Cubist Reports Second Quarter 2014 Financial Results Jul 22 2014
CUBIST PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Other... Jul 22 2014
Cubist Reports Second Quarter 2014 Financial Results Jul 22 2014
Q2 2014 Cubist Pharmaceuticals, Inc. Earnings Release - 4:00 pm ET Jul 22 2014
Top Biotech Earnings Previews for the Week Ahead Jul 20 2014
Cubist to Announce Second Quarter 2014 Financial Results on Tuesday, July 22, 2014 Jul 15 2014
Cubist to Announce Second Quarter 2014 Financial Results on Tuesday, July 22, 2014 Jul 15 2014
CUBIST PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement Jul 14 2014
If Big Pharma Ignores Antibacterial R&D, Where Will We Get The Drugs To Treat Superbugs? Jul 11 2014
[video] Cubist advances Sivextro Jun 23 2014
Cubist Pharmaceuticals (CBST) Is Water-Logged And Getting Wetter Today Jun 23 2014
Cubist Gains FDA Approval for Sivextro Jun 23 2014
Will This Price Target Increase Help Cubist Pharmaceuticals (CBST) Stock Today? Jun 23 2014
CUBIST PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 23 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide